Validation of monoplex assays detecting antibodies against Corynebacterium diphtheriae and Clostridium tetani toxins, rubella virus and parvovirus B19 for incorporation into Multiplex Serology

• Published in: Methods (San Diego, Calif.) Vol. 158; pp. 44 - 53
• Main Authors: Brenner, Nicole, Butt, Julia, Bomfim, Izaura Lima, Tabatabai, Julia, Pawlita, Michael, Schnitzler, Paul, Waterboer, Tim
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2019
• Subjects: High-throughput assay; Medicin och hälsovetenskap; Multiplex; Parvovirus B19; Serology; Vaccine-preventable diseases; C. diphtheriae; CRS; Multiplex; Parvovirus B19; GST; Serology; High-throughput assay; C. tetani; DTA; MFI; B19V; DTB; VP1u; Vaccine-preventable diseases; RP; WHO
• ISSN: 1046-2023; 1095-9130; 1095-9130
• DOI: 10.1016/j.ymeth.2019.01.013

•Assays for C. diphtheriae, C. tetani, rubella virus and parvovirus B19 were developed.•Each pathogen-specific serological assay consists of one antigen.•The assays showed mean sensitivity/specificity >90% compared to reference assays.•Each assay can be included in future studies with broader multiplex panels. Serological assays detecting antibodies in serum or plasma samples are useful and versatile instruments to investigate an individual’s infection and vaccination history, e.g. for clinical diagnosis, personal risk evaluation, and seroepidemiological studies. Multiplex Serology is a suspension bead array-based high-throughput methodology for simultaneous measurement of antibodies against multiple pathogens in a single reaction vessel, thus economizing sample volume, measurement time, and costs. We developed and validated bead-based pathogen-specific Monoplex Serology assays, i.e. assays including only antigens for the respective pathogen, to detect antibodies against Corynebacterium diphtheriae and Clostridium tetani toxins, rubella virus and parvovirus B19. The developed assays expand the portfolio of existing pathogen-specific bead-based serology assays and can be efficiently incorporated into larger Multiplex Serology panels. The newly developed Monoplex Serology assays consist of only one antigen per infectious agent, expressed as Glutathione S-transferase-fusion proteins in E. coli. Specificity, sensitivity and Cohen’s kappa statistics in comparison with routine clinical diagnostic assays were calculated for serum dilutions 1:100 and 1:1000. All pathogen-specific assays were successfully validated at both serum dilutions with the exception of rubella Monoplex Serology which showed impaired sensitivity (57.6%) at dilution 1:1000. Specificities of successfully validated Monoplex Serology assays ranged from 85.6% to 100.0% (median: 91.7%), and sensitivities from 81.3% to 95.8% (median: 90.9%); agreement with the reference assays ranged from substantial to almost perfect (kappa: 0.66–0.86, median: 0.78). Statistical performance and slim assay design enable efficient incorporation of the developed assays into Multiplex Serology.